Research conducted before clinical trials in humans, including in vitro studies and animal models. Many peptide claims are based solely on preclinical data, which has a high failure rate when translated to humans.
"Preclinical" is filed under Evidence & Research in the PeptideAtlas glossary, alongside 14 other terms in that group.
The term applies directly to 4 compound profiles here: Degarelix (evidence A), Pinealon (evidence D), Cortagen (evidence D), Amycretin (evidence C). Each profile states the strength of the human evidence rather than only what the compound is claimed to do.
1 other glossary entry refer to this term in their own definition, which is usually the fastest way to see how it is used in practice.
A protein that inhibits muscle growth. Follistatin peptides are studied for their ability to block myostatin, theoretically allowing increased muscle development. Evidence is limited to preclinical studies.
A study where participants are randomly assigned to receive either the treatment or a control (placebo or standard care). The gold standard for establishing causality in medical research.
The first stage of clinical testing in humans, typically involving 20-100 healthy volunteers. Tests safety, dosage, and side effects. Most peptides in the research pipeline are at or before this stage.
Clinical trials involving 100-300 patients with the target condition. Tests efficacy and further evaluates safety. Provides initial evidence of whether a peptide works for its intended purpose.
Compounds where this applies: Degarelix, Pinealon, Cortagen, Amycretin.
Terms that reference this one: Myostatin.
More Evidence & Research terms: Randomized Controlled Trial (RCT), Phase I Trial, Phase II Trial, Phase III Trial, Systematic Review, Meta-Analysis, In Vitro, In Vivo, Placebo Effect, p-Value, Biomarker, Endpoint, Observational Study, Publication Bias.